Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.
- EligibilityCriteria: Inclusion Criteria  Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria. Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and anti-B cell maturation antigen (BCMA) therapy], and at least 3 prior lines of therapy (LOT). Documented disease progression during or after their last anti-myeloma regimen as per IMWG. Participants must have measurable disease during screening. Have measurable disease during screening. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.  Exclusion Criteria  Active or history of central nervous system involvement with MM. Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis. Other protocol-defined Inclusion/Exclusion criteria apply. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult